Small-molecule Bax agonists for cancer therapy

Nature Communications

Volumn 5, Issue , 2014, Pages

  Xin, Meiguo ^a,f   Li, Rui ^b   Xie, Maohua ^b   Park, Dongkyoo ^b   Owonikoko, Taofeek K ^b   Sica, Gabriel L ^b   Corsino, Patrick E ^c   Zhou, Jia ^d   Ding, Chunyong ^d   White, Mark A ^d   Magis, Andrew T ^e   Ramalingam, Suresh S ^b   Curran, Walter J ^b   Khuri, Fadlo R ^b   Deng, Xingming ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^f Gainesville SW Industrial Park   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME C; PROTEIN BAX; SERINE; SMBA1; SMBA2; SMBA3; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN;

APOPTOSIS; CANCER; CHEMOTHERAPY; CYTOCHROME; ENZYME ACTIVITY; MEMBRANE; MITOCHONDRION; TOXICITY; TUMOR;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONFORMATIONAL TRANSITION; GENE SILENCING; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MOLECULAR RECOGNITION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; AGONISTS; ANIMAL; BINDING SITE; CELL LINE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; FIBROBLAST; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MOUSE; NEOPLASMS; NUDE MOUSE; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BINDING SITES; CELL LINE; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; SERINE;

EID: 84923370451     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5935     Document Type: Article

References (55)

1. Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
2. Xin, M. & Deng, X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 280, 10781-10789 (2005).
3. Xin, M. & Deng, X. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J. Biol. Chem. 281, 18859-18867 (2006).
4. Goping, I. S. et al. Regulated targeting of BAX to mitochondria. J. Cell Biol. 143, 207-215 (1998).
5. Smaili, S. S. et al. Mitochondria, calcium and pro-Apoptotic proteins as mediators in cell death signaling. Braz. J. Med. Biol. Res. 36, 183-190 (2003).
6. Nechushtan, A., Smith, C. L., Lamensdorf, I., Yoon, S. H. & Youle, R. J. Bax and Bak coalesce into novel mitochondria-Associated clusters during apoptosis. J. Cell Biol. 153, 1265-1276 (2001).
7. Mikhailov, V. et al. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J. Biol. Chem. 276, 18361-18374 (2001).
8. Xin, M., Gao, F., May, W. S., Flagg, T. & Deng, X. Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 282, 21268-21277 (2007).
9. Gardai, S. J. et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 279, 21085-21095 (2004).
10. Kim, B. J., Ryu, S. W. & Song, B. J. JNK-And p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 281, 21256-21265 (2006).
11. Linseman, D. A. et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J. Neurosci. 24, 9993-10002 (2004).
12. Suzuki, M., Youle, R. J. & Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645-654 (2000).
13. Nechushtan, A., Smith, C. L., Hsu, Y. T. & Youle, R. J. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J. 18, 2330-2341 (1999).
14. Wang, Q., Sun, S. Y., Khuri, F., Curran, W. J. & Deng, X. Mono-or double-site phosphorylation distinctly regulates the proapoptotic function of Bax. PLoS ONE 5, e13393 (2010).
15. Ewing, T. J., Makino, S., Skillman, A. G. & Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15, 411-428 (2001).
16. Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R. & Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161, 269-288 (1982).
17. Shoichet, B. K., Bodian, D. L. & Kuntz, I. D. Molecular docking using shape descriptors. J. Comput. Chem. 13, 380-397 (1992).
18. Meng, E. C., Shoichet, B. K. & Kuntz, I. D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 13, 505-524 (1992).
19. Ostrov, D. A. et al. Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J. Med. Chem. 52, 5144-5151 (2009).
20. Svejda, B. et al. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117, 4141-4154 (2011).
21. Li, R. et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 12, 2200-2212 (2013).
22. Dewson, G. et al. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ. 19, 661-670 (2012).
23. Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124-7129 (2000).
24. Zhang, H., Nimmer, P., Rosenberg, S. H., Ng, S. C. & Joseph, M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 307, 70-75 (2002).
25. Bruncko, M. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641-662 (2007).
26. Eskes, R., Desagher, S., Antonsson, B. & Martinou, J. C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 20, 929-935 (2000).
27. Ikonen, E., Fiedler, K., Parton, R. G. & Simons, K. Prohibitin, an antiproliferative protein, is localized to mitochondria. FEBS Lett. 358, 273-277 (1995).
28. Deng, X. et al. Novel role for JNK as a stress-Activated Bcl2 kinase. J. Biol. Chem. 276, 23681-23688 (2001).
29. Dewson, G. & Kluck, R. M. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J. Cell Sci. 122(Pt 16): 2801-2808 (2009).
30. Hsu, Y. T., Wolter, K. G. & Youle, R. J. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl Acad. Sci. USA 94, 3668-3672 (1997).
31. Hsu, Y. T. & Youle, R. J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J. Biol. Chem. 273, 10777-10783 (1998).
32. Sawada, M. et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5, 320-329 (2003).
33. Dewson, G. et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol. Cell 30, 369-380 (2008).
34. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
35. Puri, N. et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-3534 (2007).
36. Xing, Y. et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc. 2, 1152-1165 (2007).
37. Xu, J. et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur. J. Cancer 48, 1682-1691 (2012).
38. Huang, D. H. et al. Comparison and optimization of multiplexed quantum dotbased immunohistofluorescence. Nano Res. 3, 61-68 (2010).
39. Huang, D. H. et al. Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology 20, 225102 (2009).
40. Deng, X., Gao, F., Flagg, T., Anderson, J. & May, W. S. Bcl2's flexible loop domain regulates p53 binding and survival. Mol. Cell Biol. 26, 4421-4434 (2006).
41. Jemal, A. et al. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
42. Groeger, A. M. et al. A model of BAX gene delivery to human lung cancer. Anticancer Res. 21, 3627-3630 (2001).
43. Wolter, K. G. et al. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139, 1281-1292 (1997).
44. Antonsson, B., Montessuit, S., Lauper, S., Eskes, R. & Martinou, J. C. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem. J. 345(Pt 2): 271-278 (2000).
45. Saito, M., Korsmeyer, S. J. & Schlesinger, P. H. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat. Cell Biol. 2, 553-555 (2000).
46. Gavathiotis, E., Reyna, D. E., Bellairs, J. A., Leshchiner, E. S. & Walensky, L. D. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 8, 639-645 (2012).
47. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
48. Baggstrom, M. Q. et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J. Thorac. Oncol. 6, 1757-1760 (2011).
49. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
50. Pettersen, E. F. et al. UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
51. Dunbrack, Jr R. L. Rotamer libraries in the 21st century. Curr. Opin. Struct. Biol. 12, 431-440 (2002).
52. Adrain, C., Creagh, E. M. & Martin, S. J. Apoptosis-Associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 20, 6627-6636 (2001).
53. Liu, Y. et al. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol. Cancer Ther. 11, 45-56 (2012).
54. Liu, A. W. et al. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin. Cancer Res. 17, 710-720 (2011).
55. Wang, X. et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 7, 1952-1958 (2008).